For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

Translation to Clinic Plenary: 'Cell Therapies: Coming of Age, No Longer Just a Concept'
Thursday, May 30, 2024 01:45 PM - 03:15 PM  
Plenary Hall
Translation to Clinic
Plenary Session
Chair
  • Sowmya Viswanathan, PhD, University Health Network, Canada
Speakers
  • Bob Valamehr, PhD, Fate Therapeutics, United States, "The Development of Multiplexed-Engineered iPSC-derived CAR T Cells for the Off-the-Shelf Treatment of Cancer and Autoimmune Diseases"
  • Marcus Yountz, MD, FAAN, BlueRock Therapeutics, United States, "Developing a Dopaminergic Neuronal Precursor Cell Therapy for Parkinson’s Disease: Background
    and 18-month Results from a Phase 1 Study of Bemdaneprocel"
  • Sai Kiang Lim, PhD, A*Star Institute of Molecular Biology, Singapore, "Clinical MSC-EVs: CMC, Manufacturing and Scalability"

Cell and gene therapies have evolved from an academic concept to a full-fledged reality, reshaping the landscape of intractable disease treatment. This plenary will delve into the transformative potential of these revolutionary treatments for diseases such as Parkison’s, blood cancers, and autoimmune diseases.

Explore current manufacturing and regulatory challenges and how they are being tackled. Keep up with recent advances and challenges in the development of cellular nanoparticles for therapeutic applications. Join us in unravelling the potential and complexities of these groundbreaking treatments that are at the forefront of medical innovation. 

Sai Kiang Lim
Research Director
Paracrine Therapeutics
Speaker


Sowmya Viswanathan
Scientist
Schroeder Arthritis Institute, University Health Network
Chair


Marcus Yountz
Vice President, Clinical Development, Neurology
BlueRock Therapeutics
Speaker


Bob Valamehr
Chief Research and Development Officer
Fate Therapeutics, Inc.
Speaker